ArticleGastroenterology & hepatology2021
Efficacy and Safety of Dual Biologic Therapy in Patients With Inflammatory Bowel Disease: A Review of the Literature.
Article in Gastroenterology & hepatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06520397 (Evaluation of the Efficacy and Safety of Dual-targeted Therapy With Upadacitinib and Ustekinumab Versus Intensified Ustekinumab Therapy in Crohn's Disease Patients With an Insufficient Response to Standard-dose Ustekinumab), which is not on this map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of the Efficacy and Safety of Dual-targeted Therapy With Upadacitinib and Ustekinumab Versus Intensified Ustekinumab Therapy in Crohn's Disease Patients With an Insufficient Response to Standard-dose Ustekinumab: A Randomized Controlled Trial
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 40 citations in OpenAlex.
- Safety and efficacy of advanced combination therapies for treating inflammatory bowel disease in adults: a systematic review and meta-analysis.BMJ open gastroenterology · 2026Pooled it
- Cost-Effectiveness Analysis of Tofacitinib Compared with Biologics in Biologic-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan.PharmacoEconomics · 2023Pooled it
- Expanding treatment frontiers in hidradenitis suppurativa: Double immunomodulator therapy in severe refractory cases.JAAD case reports · 2026Article
- [Advanced Combination Therapy in Inflammatory Bowel Disease].The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2026Review
- Comparative Effectiveness of Dual Biologic Therapy and Biologic Small-Molecule Therapy for Refractory Inflammatory Bowel Disease: A Retrospective Single-Center Study.Clinical and translational science · 2025Article
- New perspectives and prospects for the next generation of combination therapy in inflammatory bowel disease.World journal of gastroenterology · 2025Article
- Review
- Combining Advanced Targeted Therapy in Inflammatory Bowel Disease: Current Practice and Future Directions.Journal of clinical medicine · 2025Article
- Impact of exercise on outcomes among Chinese patients with Crohn's disease: a mixed methods study based on social media and the real world.BMC gastroenterology · 2024Article
- Dual-targeted treatment for inflammatory bowel disease: Whether fecal microbiota transplantation can be an important part of it.World journal of gastroenterology · 2024Article
- Back to the drawing board: Overview of the next generation of combination therapy for inflammatory bowel disease.World journal of gastroenterology · 2024Review
- Combination treatment of inflammatory bowel disease: Present status and future perspectives.World journal of gastroenterology · 2024Article
- Immunogenicity and Loss of Effectiveness of Biologic Therapy for Inflammatory Bowel Disease Patients Due to Anti-Drug Antibody Development.Antibodies (Basel, Switzerland) · 2024Review
- Current Evidence for Combined Targeted Therapy for the Treatment of Inflammatory Bowel Disease.Journal of the Canadian Association of Gastroenterology · 2024Review
- Advanced combination therapy: is it the best way to break the therapeutic ceiling?Therapeutic advances in gastroenterology · 2024Review
- Understanding the molecular mechanisms of anti-trafficking therapies and their clinical relevance in inflammatory bowel disease.Mucosal immunology · 2023Review
- Role of Biologic Therapies in the Rheumatic Manifestations of Inflammatory Bowel Disease: A Systematic Analysis.Cureus · 2023Review
- Emerging role of dual biologic therapy for the treatment of inflammatory bowel disease.World journal of clinical cases · 2023Review
- The SYSCID map: a graphical and computational resource of molecular mechanisms across rheumatoid arthritis, systemic lupus erythematosus and inflammatory bowel disease.Frontiers in immunology · 2023Article
- Dual biologic therapy for the treatment of rheumatic diseases and asthma: a case series.Rheumatology advances in practice · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
34602905PMC8475252W3204861196What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.